Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity
Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity
批准号:
10204509
负责人:
Jane Hoyt Buckner
金额:
$210.02万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-04 至 2023-03-31
关键词:
AddressAutoimmune DiseasesAutoimmunityCD8-Positive T-LymphocytesCell LineageCell physiologyCellsChemosensitizationChronic Childhood ArthritisClinicalClinical TrialsDataDevelopmentDiseaseEquilibriumFundingGeneticGenetic TranscriptionGenotypeGoalsGrantHomingHumanIL6 Signaling PathwayImmunologicsImmunologyImmunophenotypingIndividualInflammatory ResponseInsulin-Dependent Diabetes MellitusInterleukin 6 ReceptorInterleukin-6KnowledgeL-SelectinLeadLinkMeasuresMediatingMembraneMultiple SclerosisOutcomePathogenesisPathogenicityPathway interactionsPhosphorylationPlayPublic HealthRegulationRegulatory T-LymphocyteRelapsing-Remitting Multiple SclerosisResearchResearch Project GrantsResistanceResolutionRheumatoid ArthritisRoleSTAT1 geneSTAT3 geneSignal TransductionSpecificitySystemT cell responseT-LymphocyteTherapeuticTranslationsVariantWorkadaptive immunityautoreactive T cellbasecohortcytokineeffector T cellinsightisletlymph nodespatient responseprimary endpointprogramsreceptor expressionresponsetargeted treatmenttraffickingtranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT
The IL-6 signaling pathway is dysregulated in autoimmunity in part through increased expression of the
membrane bound IL-6R (mbIL-6R). The central hypothesis for the proposed studies is that elevated mbIL-6R
expression leads to altered T cell fate and function resulting in pathogenic autoreactive T cells due to changes
in the magnitude and balance of STAT1 and STAT3 phosphorylation. The following three Specific Aims will
address this hypothesis. Aim 1 studies will determine the regulation of mbIL-6R expression in T cells from type
1 diabetes (T1D), relapsing remitting multiple sclerosis (RRMS) and rheumatoid arthritis (RA) subjects at the
genetic, transcriptional, translational and post-translation level, focusing on the contribution of the
IL6RAsp358Ala variant and ADAM17 mediated shedding. Aim 2 studies will determine how increased mbIL-6R
alters the magnitude and balance of STAT1 and STAT3 phosphorylation and how these changes influence the
T cell response with respect to lineage commitment, homing and response to regulation. These studies will
take advantage of a cohort of healthy subjects with genetically determined mbIL-6R expression levels. Aim 3
studies will determine the impact of elevated mbIL-6R expression on both total T cells and autoreactive T cells
in T1D, RRMS and RA. The primary endpoints will be T cell lineage commitment, transcriptional profile, and
response to regulation. This aim will also determine the effect of elevated mbIL-6R expression on the islet
specific T cell response to tocilizumab in T1D. The studies proposed in this application are appropriate for the
“High Priority Immunology Grant (R01)” mechanism as it is research investigating the immunological
mechanisms of autoimmune disease pathogenesis using well-defined human cohorts, high resolution
immunophenotyping and systems immunology. These studies will advance our understanding of how subtle
alterations in IL-6 signaling, contribute to the development and potentiation of autoimmunity.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fimmu.2022.972121
发表时间:
2022
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[]
通讯作者:
DOI:
10.1172/jci.insight.159436
发表时间:
2022-11-22
期刊:
JCI INSIGHT
影响因子:
8
作者:
[Speake, Cate, Habib, Tania, Lambert, Katharina, Hundhausen, Christian, Lord, Sandra, Dufort, Matthew J., Skinner, Samuel O., Hu, Alex, Kinsman, MacKenzie, Jones, Britta E., Maerz, Megan D., Tatum, Megan, Hocking, Anne M., Nepom, Gerald T., Greenbaum, Carla J., Buckner, Jane H.]
通讯作者:
Buckner, Jane H.
Clinical and experimental treatment of type 1 diabetes.
1 型糖尿病的临床和实验治疗。
DOI:
10.1093/cei/uxac077
发表时间:
2022
期刊:
Clinical and experimental immunology
影响因子:
4.6
作者:
[Long,SAlice, Buckner,JaneH]
通讯作者:
Buckner,JaneH
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease
-
批准号:10871040
-
项目类别:
-
资助金额:$49.27万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
T cells promoting transitions toward autoimmunity
-
批准号:10658696
-
项目类别:
-
资助金额:$131.63万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease (Admin Supp)
-
批准号:10933073
-
项目类别:
-
资助金额:$26.02万
-
财政年份:2023
-
负责人:Jane Hoyt Buckner
-
依托单位:
Harnessing engineered T regulatory cells to promote beta cell health in T1D
-
批准号:10436687
-
项目类别:
-
资助金额:$99.34万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Clinical Core
-
批准号:10420945
-
项目类别:
-
资助金额:$32.63万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Harnessing engineered T regulatory cells to promote beta cell health in T1D
-
批准号:10605317
-
项目类别:
-
资助金额:$97.57万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Clinical Core
-
批准号:10598119
-
项目类别:
-
资助金额:$103.61万
-
财政年份:2022
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10248349
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10480055
-
项目类别:
-
资助金额:$90.13万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Anti-tumor and autoimmunity signatures in Down syndrome
-
批准号:10848979
-
项目类别:
-
资助金额:$64.88万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:9812541
-
项目类别:
-
资助金额:$87.48万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
-
批准号:10682446
-
项目类别:
-
资助金额:$84.56万
-
财政年份:2019
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the functional impact of T1D genes in mouse and man: a unified strategy
-
批准号:8686992
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8680005
-
项目类别:
-
资助金额:$245.08万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the functional impact of T1D genes in mouse and man: a unified strategy
-
批准号:8436004
-
项目类别:
-
资助金额:$425.86万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8492031
-
项目类别:
-
资助金额:$230.37万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Defining the role of altered cytokine signaling pathways on autoimmunity
-
批准号:8373725
-
项目类别:
-
资助金额:$245.08万
-
财政年份:2012
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8705359
-
项目类别:
-
资助金额:$44.58万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8042482
-
项目类别:
-
资助金额:$42.91万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
Impact of the autoimmunity associated PTPN22 1858T
-
批准号:8517562
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2011
-
负责人:Jane Hoyt Buckner
-
依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
-
批准号:31171277
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:Christine Nardini
-
依托单位: